- UCB is planning to open a new manufacturing facility in the United States to meet rising demand and support its growing pipeline.
- The project is expected to generate around 300 permanent jobs and 500 construction roles, reinforcing the company’s long-term U.S. commitment.
UCB, a global biopharmaceutical company focused on severe diseases, has announced plans to significantly expand its manufacturing capacity in the United States. The new facility will support the company’s growing pipeline and help ensure dependable access to its medicines.
The site will integrate with UCB’s global manufacturing network and scale-up efforts with U.S.-based contract manufacturing organisations (CMOs). It is designed to strengthen supply chain resilience while advancing the company’s sustainability goals.
The expansion is expected to create approximately 300 permanent roles in biologics manufacturing and an additional 500 jobs during construction. UCB already employs around 2,000 people in the U.S. across eight research and commercial offices.
Over the past five years, UCB has invested $4.5 billion in U.S.-based acquisitions and capital projects and has received 15 FDA approvals or indication expansions—eight of which were granted in the last two years.
“As with everything we do, this expansion will reflect our values,” the company stated, noting that environmental sustainability and digital efficiency are key considerations in the facility’s design.
